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Abstract
Background: Glycogen storage disease type III (GSD
III) is caused by mutations in AGL which encodes for
a single protein with two enzyme activities: oligo-1,
4-1, 4-glucantransferase (transferase) and amylo-1,
6-glucosidase. Activity of both enzymes is lost in most
patients with GSD III, but in the very rare subtype IIId,
transferase activity is deficient. Since the spectrum of
AGL mutations is dependent on the ethnic group, we
investigated the clinical and molecular characteristics
in Egyptian patients with GSD III.
Methods: Clinical features were examined in five
Egyptian patients. AGL was sequenced and AGL
haplotypes were determined.
Results: Six novel AGL mutations were identified: a
large deletion (c.3481–3588q1417del1525 bp), two
insertions (c.1389insG and c.2368insA), two small
deletions (c.2223–2224delGT and c.4041delT), and a
missense mutation (p.L620P). p.L620P was found in a
patient with IIId. Each mutation was located on a
different AGL haplotype.
Conclusions: Our results suggest that there is allelic
and phenotypic heterogeneity of GSD III in Egypt. This
is the second description of a large deletion in AGL.
p.L620P is the second mutation found in GSD IIId.
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Introduction
Glycogen storage disease type III (GSD III; MIM
232400) is an autosomal recessive inherited disor-
der characterized by hepatomegaly, growth retarda-
tion and fasting hypoglycemia (1, 2). GSD III is caused
by a deficiency in the glycogen debranching enzyme,
a key enzyme in the degradation of glycogen. The
enzyme has two independent catalytic activities, oligo-1,
4-1, 4-glucantransferase (EC 2.4.1.25) (transferase)
and amylo-1, 6-glucosidase (EC 3.2.1.33) (glucosidase),
located on a single 160-kDa protein. Activity of both
enzymes is virtually absent in affected organs. Most
patients have both liver and muscle involvement
(GSD IIIa), but ;15% of the patients have liver
involvement only and without any muscular manifes-
tations (GSD IIIb). Rarely, patients have been catego-
rized with selective loss of one of two enzyme
activities (3, 4). Selective transferase deficiency is
named GSD IIId. However, the molecular basis for
GSD IIId has not been fully elucidated.
A gene coding human glycogen debranching
enzyme (gene symbol: AGL) has been isolated and
shown to be 85 kb in length and composed of 35
exons, encoding a 7.0-kb mRNA (5). Molecular anal-
yses of GSD III have been performed in several ethnic
populations, and over 60 different AGL mutations
have been reported to date in GSD III patients (Human
Gene Mutation Database; http://www.hgmd.cf.ac.uk/
ac/index.php). A majority of AGL mutations have
been point mutations, small deletions, insertions, or
splicing mutations. However, a large deletion has
been reported in the single case (6). Since eight mis-
sense mutations have been reported in AGL (7–10),
whether these are responsible for GSD III remains
unclear. Only G1448R has been characterized in vitro
(11).
The spectrum of AGL mutations in GSD III depends
on the ethnic group. In an ethnic group with high rate
of consanguinity, prevalent mutations have been
reported (12, 13). In Egypt, the incidence of consan-
guineous marriages in the general population is
reported to be ;29% (14). However, three different
AGL mutations have been identified in three patients
from the Delta region in Egypt (15). To investigate the
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molecular characteristics further, we examined five
new cases and detected a total of six novel mutations,
including the second large deletion and a novel mis-




Five Egyptian GSD III patients from five families from Cairo
and Alexandria, Egypt were investigated. The patients were
confirmed as having deficient debranching enzyme activity
in peripheral blood cells by the method of Shin (16). This
method assessed a reverse incorporation of isotope-labeled
glucose into glycogen, whereby measured activity reflects
primarily that of glucosidase. Because IIId has residual glu-
cosidase activity, this method enabled us to distinguish IIId
from IIIa or IIIb (2). Tissue samples from liver or muscle were
unavailable for use in this study. Consanguinity was ascer-
tained in three out of five families. The study was approved
by the Local Ethics Committees and performed with the
patients’ and their families’ informed consent.
DNA sequence analysis of AGL
Genomic DNA was isolated from peripheral blood
leukocytes.
The full coding exons, their relevant exon-intron bounda-
ries, and the 59- and 39-flanking regions of the patients’ AGL
were sequenced directly as described previously (17). In
brief, 11 DNA fragments to cover AGL were amplified from
genomic DNA by LA-PCR. LA-PCR products were recovered
and subjected to direct sequencing with internal sequencing
primers. The nucleotides of AGL cDNA were numbered
according to AGL isoform 1 (GenBank accession no.
NM_000642).
For the detection of the large deletion around exon 27, LA-
PCR was performed for 30 cycles of denaturation and
annealing/extension at 948C for 30 s and 688C for 5 min,
respectively. The fragments were then electrophoresed on a
0.9% agarose gel.
Point mutations that were identified in patients were
verified using restriction fragment length polymorphism
(RFLP) analyses. A pair of primers (listed in Table 1) was
used for PCR, and each specific restriction endonuclease was
added to digest PCR products. Restriction digests were ana-
lyzed on polyacrylamide gel.
Fifty Egyptian control subjects were examined with LA-
PCR and RFLP analyses in the same manner in order to rule
out the possibility that there are mere polymorphisms in
controls.
Haplotype determination in AGL
A total of 30 single nucleotide polymorphisms (SNPs) in AGL
were determined as described previously (18).
RT-PCR analysis of the AGL cDNA
Total RNA was isolated from whole blood samples from
patient 1 and a normal control using QIAamp RNA blood
mini kits (QIAGEN, Düsseldorf, Germany), and reverse tran-
scribed into single strand cDNA using random hexamers and
Superscript II (Invitrogen, Carlsbad, CA, USA). AGL cDNA
fragments were amplified by PCR and electrophoresed on
0.9% agarose gel as described previously (19). In addition,
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Figure 2 Schematic representation of 1525 bp deletion in
patient 1 (c.3481–3588q1417del1525 bp).
The 39-part of exon 27 plus the 59-part of intron 27 were
deleted.
Figure 1 Identification of six novel AGL mutations.
Upper panel: Sequence electropherograms of patients 1–5, and those of a control. Lower panel: Mutational analysis. LA-PCR
products were electrophoresed directly on agarose gel. In RFLP analyses, PCR products following digestion with restriction
endonucleases were electrophoresed on polyacrylamide gels. M, DNA marker; P1–P5, patients 1–5; C, control. (A) Patient 1
had a shorter 624-bp fragment in LA-PCR around exon 27, showing that patient 1 was homozygous for the large deletion
(c.3481–3588q1417del1525 bp). (B) In BslI RFLP analysis, patient 2 had both normal 123- and mutant 98-bp fragments, indi-
cating that patient 2 was heterozygous for c.1389insG. (C) Patient 2 had normal 136- and mutant 83- and 51-bp fragments in
MslI RFLP analysis, verifying that patient 2 was also heterozygous for c.2223–2224delGT. (D) In StuI RFLP analysis, patient 3
had an uncleaved 147-bp fragment, indicating that patient 3 was homozygous for p.L620P. (E) In PsiI RFLP analysis, patient
4 had mutant 139- and 46-bp fragments, showing that patient 4 was homozygous for c.2368insA. (F) Patient 5 had a mutant
281-bp fragment in DraI RFLP, verifying that patient 5 was homozygous for c.4041delT.
PCR was performed using a sense primer in exon 26 (59-CTT
ACC TCA TTT TTC TTC TGG-39) and an antisense primer in
exon 29 (59-CAT GTG CCA CAA TTG AAA CG-39) to examine
whether aberrant spliced cDNA was detected in patient 1.
Bioinformatical analysis
Repetitive sequences, such as Alu elements were searched
using RepeatMasker software by Smit AFA, Hubley R and
Green P (http://repeatmasker.org). Nucleotide sequences of
intron 27 in AGL were retrieved from Homo sapiens chro-
mosome 1 genomic contig NT_032977. Alignment of amino
acid sequences from various species was performed with
ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/) (20).
Results
We identified six AGL mutations in five Egyptian
patients. All were novel mutations and none were
found in the 50 Egyptian controls. Four patients were
homozygotes and patient 2 was a compound hetero-
zygote. None of the patients had mutations in exon 3,
indicating that none were IIIb. Sequence electrophe-
rograms and RFLP analyses are shown in Figure 1.
Patient 1 was homozygous for a large deletion
involving exon 27. LA-PCR fragment encompassing
exons 25–28 was shorter than that from a control
(data not shown). To further narrow the location, we
designed a forward primer in exon 27 and a reverse
primer in exon 28 as shown in Table 1. The LA-PCR frag-
ment (exon 27 to exon 28) from patient 1 was shorter
than that from a control (Figure 1A). Sequence analysis
showed a deletion of 1525 bp (g.70,338,229–
70,339,753 in NT_032977). One hundred and eight bp
of the 39-part of exon 27 (c.3481–3588) plus 1417 bp
of the 59-part of intron 27 (c.3481–3588q1417del1525
bp) was deleted, as illustrated in Figure 2. The dele-
tion contained 108-bp coding sequences in exon 27
and presumably caused an in-frame deletion of 36
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Figure 3 Comparison of amino acid sequences around the
620th amino acid of glycogen debranching enzymes from
various species.
Identical amino acids are represented as – – –. An arrow
indicates the human leucine at codon 620 and the consensus
sequence four in the a-amylase superfamily are boxed. The
species and the NCBI accession numbers are as follows:
human (Homo sapiens), NP_000019; dog (Canis familiaris),
XP_537057; cow (Bos taurus) predicted protein, XP_595566,
chicken (Gallus gallus) predicted protein, XP_422317; mouse
(Mus musculus), NP_001074795; mosquito (Anopheles
gambiae), XP_321957; fruitfly (Drosophila melanogaster),
NP_726062; Caenorhabditis elegans, hypothetical protein,
NP_496984.
amino acid residues. In order to examine aberrant
splicing which could be caused by this deletion, RT-
PCR using a pair of primers in exons 26 and 29 was
performed. No PCR fragments were detected from
patient 1, while the expected 516-bp fragment was
obtained from a control sample (data not shown). A
nucleotide homology search showed little homology
between breakpoint flanking sequences. In addition,
no Alu repetitive elements were found in intron 27 by
the RepeatMasker software.
Sequence analysis of patient 2 showed an insertion
of G at nucleotide 1389 in exon 12 (c.1389insG).
Further sequencing analysis for patient 2 revealed a
deletion of GT at nucleotides 2223 and 2224 in exon
18 (c.2223–2224delGT). Thus, patient 2 was a com-
pound heterozygote for c.1389insG and c.2223–
2224delGT.
Patient 3 was homozygous for a missense mutation
in exon 15. Sequence analysis of patient 3 showed a
T-to-C substitution at nucleotide 1859 in exon 15. This
replaces leucine by proline at codon 620 (p.L620P). No
mutations, except p.L620P, were found in patient 3.
Comparison of amino acid sequences among glyco-
gen debranching enzymes from various species
showed that leucine at codon 620 was well preserved
during evolution, as shown in Figure 3. In addition,
leucine at codon 620 was located in the consensus
sequence four in the a-amylase superfamily (21, 22),
suggesting that this amino acid is important for
enzyme activity.
Patient 4 had an insertion of A at nucleotide 2368
in exon 19 (c.2368insA). Patient 5 had a deletion of T
at nucleotide 4041 in exon 31 (c.4041delT). Haplotype
analysis of six mutant alleles demonstrated that each
mutation was located on a different AGL haplotype
(Table 2).
Clinical features and enzyme activities in patients
are shown in Table 2. All patients had hepatomegaly
and deficient enzyme activity. They did not show
muscle weakness, which was consistent with the pre-
vious finding that muscle weakness is usually mini-
mal during childhood in patients with GSD IIIa (1). Of
note, patient 3 had residual enzyme activity and no
episodes of hypoglycemia. This may be consistent
with glucose release by glucosidase not being com-
pletely absent. A liver biopsy proved accumulation of
glycogen and liver enzyme activities were increased
in patient 3: alanine aminotransferase (ALT) 438 IU/L
(normal range: 6–50 IU/L) and aspartate aminotrans-
ferase (AST) 363 IU/L (normal range: 11–38 IU/L).
Discussion
Our genetic analysis of five Egyptian patients
revealed six novel AGL mutations, including the sec-
ond large deletion and p.L620P. In addition, haplotype
analysis demonstrated that each mutation was locat-
ed on a different AGL haplotype. These findings sup-
port the notion that heterogeneous mutations are
responsible for Egyptian GSD III patients.
A large deletion in AGL was identified in patient 1.
The large deletion (c.3481–3588q1417del1525 bp)
results in a missing 108-bp of 39-part of exon 27,
which could not alter the reading frame for amino
acids, if the resulting exon 27 was spliced and com-
bined with exon 28. However, RT-PCR did not detect
any fragments from patient 1, suggesting that neither
authentic nor cryptic splicing occurred and that there
were no detectable AGL mRNA due to the deletion.
Some of the large deletions were caused by Alu
repetitive elements mediated recombination, as we
described previously (23), but this was not the case in
patient 1. In this patient, no repetitive elements were
identified around the junction. Since there was little
homology between breakpoint flanking sequences in
exon 27 and intron 27, a mechanism for this large
deletion could be non-homologous end-joining,
which is thought to be responsible for deletions in
genetic diseases (24–26). Very recently, another large
deletion has been reported in an Egyptian patient (6).
Thus, our case is the second large deletion in AGL.
Two novel small deletions (c.2223–2224delGT and
c.4041delT) and two novel insertions (c.1389insG and
c.2368insA) are predicted to lead to premature ter-
mination due to a frame shift which completely abol-
ishes enzyme activity. These premature stop codons
are likely to be recognized by non-sense-mediated
mRNA-decay machinery, leading to absence of AGL
mRNA.
A novel missense mutation, p.L620P, was found in
patient 3. The leucine at codon 620 in glycogen
debranching enzymes is well preserved among vari-
ous species and was located in the consensus
sequence four in the a-amylase superfamily. An ami-
no acid substitution (corresponding to amino acids in
exon 15 in the human AGL) results in loss of trans-
ferase activity, but glucosidase activity remains in a
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Table 2 Clinical and genetic features in 5 Egyptian patients.
Patient 1 2 3 4 5
Clinical features
Age, years/sex 4/Male 3/Male 4/Female 5/Female 9/Female
Hepatomegaly q q q q q
Hypoglycemia q q – q q
Muscle weakness – – – – –
Enzyme activitya 0 0 0.05 0 0
Subtype IIIa IIIa IIId IIIa IIIa
Consanguinity – – q q q
Mutation Large deletion Insertion, deletion Missense Insertion Deletion
Mutation 1b c.3481–3588q1417del1525 bp c.1389insG c.1859T)C c.2368insA c.4041delT
(p.L620P)
Mutation 2 c.2223–2224delGT
Homozygote Compound heterozygote Homozygote Homozygote Homozygote
Exon 27 12, 18 15 19 31
SNPs
–1246 aa aa aa aa cc
–787 aa aa aa aa aa
–10 in exon 3 gg ag aa gg gg
IVS3q85 tt tt cc tt tt
–2 in Ex49 cc ct cc cc cc
IVS4–122 tt tt tt tt tt
IVS5–53 cc cc gg cc cc
IVS6–73 gg ag aa gg gg
L298L tt tt cc tt tt
IVS8–18 aa aa gg aa aa
R387Q RR RR RR RR RR
IVS10q15 tt tt tt tt cc
IVS12q74 tt cc cc tt tt
IVS12–125 aa at tt aa aa
IVS12–44 aa aa aa gg gg
IVS13–70 cc cg cc gg gg
IVS14q38 gg gg gg gg gg
IVS16q8 cc ct tt cc cc
IVS18q215 cc cg cc cc cc
IVS21q124 aa ag gg aa aa
IVS22q11 aa gg gg aa gg
IVS23–121 gg ag aa gg gg
IVS23–21 aa at tt aa aa
P1067S PP PP PP PP PP
G1115R GG GG GG GG GG
R1253H RR RR RR RR RR
IVS29q45 gg ag gg aa gg
IVS29q53 tt at tt aa tt
El343K EE EE EE EE EE
IVS32–97 gg ag gg aa gg
ammol/min/gHb, normal range: 0.6–3.5. bNucleotide numbering starts at the initiation codon.
yeast glycogen debranching enzyme (22). Further-
more, we expressed p.L620P mutant and normal AGL
proteins in COS cells transiently, and measured both
glucosidase and transferase activities. The p.L620P
exhibited complete loss of transferase activity, but
retained glucosidase activity compared with wild type
AGL (27). Thus, p.L620P was responsible for GSD IIId
in patient 3.
According to the available literature, GSD IIId
patients are very rare and only one mutation has been
reported: a 4-bp deletion in exon 10 (28). This deletion
was probably associated with skipping of the follow-
ing exon (98 bp) in the mRNA level, leading to an
in-frame mutation with loss of the corresponding 34
amino acids in exon 11. However, this was not veri-
fied with in vitro expression analysis. An amino acid
homology search predicted that a putative active site
for enzyme activity was located in exons 6, 13, 14, and
15 (5). Presumably, missense mutations or in-frame
deletions near these exons are more likely to cause
GSD IIId, but this needs to be verified by further stud-
ies. Accordingly, p.L620P is the second mutation
associated with GSD IIId.
In summary, we identified six novel AGL mutations,
including the second case of the large deletion in AGL
and the second mutation in GSD IIId, and showed
allelic and phenotypic heterogeneity in Egypt.
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